U.S. market Closed. Opens in 17 hours 16 minutes

BDXB | Becton, Dickinson and Company Stock Overview

(Stock Exchange: NYSE)
Day's Range 47.65 - 48.82
52 Week Range 45.85 - 52.52
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 2,764,320
Average Volume 449,584
Shares Outstanding 284,293,034
Market Cap 13,691,552,517
Sector Healthcare
Industry Medical - Instruments & Supplies
IPO Date 2020-05-21
Valuation
Profitability
Growth
Health
P/E Ratio 7.60
Forward P/E Ratio N/A
EPS 6.33
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 77,000
Country USA
Website BDXB
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
BDXB's peers: ZTEK, KRMD, LMAT, PDEX, WRBY, BKDT
*Chart delayed
Analyzing fundamentals for BDXB we got that it has weak fundamentals where Valuation is considered to be fairly valued, Profitability is unacceptably poor, Growth is very good and Health is very weak. For more detailed analysis please see BDXB Fundamentals page.

Watching at BDXB technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on BDXB Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙